January 29, 2011 -- Sinopharm Group will pay $198 million for a 60% stake in Hubei drug distributor Le Ren Tang; Kelun Pharma will acquire 80% ownership of Guilin Dahua Pharma, an API company, for $21.9 million; Golden Meditech raised $34.7 million through a secondary listing in Taiwan; Bohai Pharma brought in $1.87 million via a private placement; China National Pharmaceutical Group (Sinopharm) will invest $200 million to build a manufacturing facility in Vietnam; Tianyin Pharma completed building an antibiotic manufacturing plant near Chengdu; BMI upped its short-term CAGR for the China pharma market to 16.4%; Boston Scientific started a China trial of its Promus™ drug eluting stent; 3SBio Inc. was granted SFDA approval for an extension of the TPIAO label; and First China Pharmaceutical Group won exclusive distributor rights for an anti-arrhythmia treatment. More details....
